NO20015544L - Glykosaminoglykaner med en gjennomsnittlig molekylvekt lik - Google Patents

Glykosaminoglykaner med en gjennomsnittlig molekylvekt lik

Info

Publication number
NO20015544L
NO20015544L NO20015544A NO20015544A NO20015544L NO 20015544 L NO20015544 L NO 20015544L NO 20015544 A NO20015544 A NO 20015544A NO 20015544 A NO20015544 A NO 20015544A NO 20015544 L NO20015544 L NO 20015544L
Authority
NO
Norway
Prior art keywords
glycosaminoglycans
molecular weight
average molecular
weight equal
treatment
Prior art date
Application number
NO20015544A
Other languages
English (en)
Other versions
NO20015544D0 (no
NO328902B1 (no
Inventor
Luigi De Ambrosi
Israel Hanin
Jawed Fareed
John Lee
Stanley Lorens
Ronald F Mervis
Original Assignee
Cornelli Umberto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cornelli Umberto filed Critical Cornelli Umberto
Publication of NO20015544D0 publication Critical patent/NO20015544D0/no
Publication of NO20015544L publication Critical patent/NO20015544L/no
Publication of NO328902B1 publication Critical patent/NO328902B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
    • C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
    • C08B37/0078—Degradation products

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Polymers & Plastics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Separation Using Semi-Permeable Membranes (AREA)
  • Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
  • Treatments Of Macromolecular Shaped Articles (AREA)
NO20015544A 1999-05-14 2001-11-13 Anvendelse av glykosaminoglykaner med en midlere molekylvekt lik 2400D for fremstilling av en farmasoytisk sammensetning for behandling av senil demens NO328902B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1999MI001066A IT1312107B1 (it) 1999-05-14 1999-05-14 Glicosaminoglicani aventi peso molecolare medio di 2400 d atti altrattamento della demenza senile
PCT/EP2000/004311 WO2000069444A1 (en) 1999-05-14 2000-05-12 Glycosaminoglycans having an average molecular weight equal to 2400 d suitable for the treatment of senile dementia

Publications (3)

Publication Number Publication Date
NO20015544D0 NO20015544D0 (no) 2001-11-13
NO20015544L true NO20015544L (no) 2002-01-14
NO328902B1 NO328902B1 (no) 2010-06-14

Family

ID=11382970

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20015544A NO328902B1 (no) 1999-05-14 2001-11-13 Anvendelse av glykosaminoglykaner med en midlere molekylvekt lik 2400D for fremstilling av en farmasoytisk sammensetning for behandling av senil demens

Country Status (22)

Country Link
US (1) US6979680B1 (no)
EP (1) EP1181024B1 (no)
JP (1) JP2002544233A (no)
KR (1) KR100711142B1 (no)
CN (1) CN1178667C (no)
AT (1) ATE288761T1 (no)
AU (1) AU764743C (no)
CA (1) CA2373975A1 (no)
CZ (1) CZ20014092A3 (no)
DE (1) DE60018061T2 (no)
DK (1) DK1181024T3 (no)
ES (1) ES2237425T3 (no)
HK (1) HK1039903B (no)
HU (1) HUP0201100A3 (no)
IL (1) IL146458A0 (no)
IT (1) IT1312107B1 (no)
NO (1) NO328902B1 (no)
PL (1) PL198016B1 (no)
PT (1) PT1181024E (no)
RU (1) RU2248800C2 (no)
WO (1) WO2000069444A1 (no)
ZA (1) ZA200109331B (no)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1344781A1 (en) * 2002-03-12 2003-09-17 Laboratori Derivati Organici S.P.A. Process for the depolymerization of glycosaminoglycanes and products obtained therefrom
ITMI20031023A1 (it) 2003-05-21 2004-11-22 Umberto Cornelli Glicosaminoglicani aventi peso molecolare medio 2400 d atti al trattamento delle disfunzioni emozionali.
EP1524276A1 (en) * 2003-10-16 2005-04-20 Laboratori Derivati Organici S.P.A. Multistep process for the physical depolymerization of heparin and products obtained therefrom
US7939512B2 (en) 2004-10-13 2011-05-10 Laboratori Derivati Organici Spa Multistep process for the physical depolymerization of heparin and products obtained therefrom
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
WO2009007224A1 (en) * 2007-07-10 2009-01-15 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Low molecular weight heparin derivatives having neuroprotective activity
WO2009142550A2 (en) 2008-05-22 2009-11-26 Vladimir Yegorovich Balakin Charged particle beam extraction method and apparatus used in conjunction with a charged particle cancer therapy system
WO2009142549A2 (en) 2008-05-22 2009-11-26 Vladimir Yegorovich Balakin Multi-axis charged particle cancer therapy method and apparatus
US8896239B2 (en) 2008-05-22 2014-11-25 Vladimir Yegorovich Balakin Charged particle beam injection method and apparatus used in conjunction with a charged particle cancer therapy system
CA2725498C (en) 2008-05-22 2015-06-30 Vladimir Yegorovich Balakin Multi-field charged particle cancer therapy method and apparatus
WO2009142547A2 (en) 2008-05-22 2009-11-26 Vladimir Yegorovich Balakin Charged particle beam acceleration method and apparatus as part of a charged particle cancer therapy system
BRPI0924903B8 (pt) 2009-03-04 2021-06-22 Zakrytoe Aktsionernoe Obshchestvo Protom aparelho para geração de um feixe de íons negativos para uso em uma terapia por radiação de partículas carregadas e método para geração de um feixe de íons negativos para uso com terapia por radiação de partículas carregadas
US8609097B2 (en) * 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
US20140302510A1 (en) * 2012-04-06 2014-10-09 Centre National De La Recherche Scientifique Method of diagnosis, prognostic or treatment of neurodegenerative diseases
CN112426434A (zh) * 2020-11-04 2021-03-02 山东大学 硫酸乙酰肝素在防治阿尔兹海默症中的应用
CN114478816A (zh) * 2022-02-11 2022-05-13 上海兴糖生物技术有限公司 一种白玉蜗牛多糖及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
US4847338A (en) * 1985-03-28 1989-07-11 University Of Iowa Research Foundation Low molecular weight heparin fragments as inhibitors of complement activation
US4769696A (en) * 1986-05-01 1988-09-06 Toppan Printing Co., Ltd. Scanner set-up simulation apparatus
IT1213384B (it) * 1986-11-24 1989-12-20 Lab Derivati Organici Mediolan Processo per la preparazione controllata di gilcosaminoglicani a basso peso molecolare.
IT1205042B (it) * 1987-05-28 1989-03-10 Crinos Industria Farmaco Composizione farmaceutica ad attivita' terapeutica per il trattamento della demenza senile di tipo alzheimer
EP0337327A1 (en) * 1988-04-09 1989-10-18 Bioiberica, S.A. Process for the preparation of new oligosaccharide fractions by controlled chemical depolimerization of heparin
IT1240615B (it) * 1990-04-03 1993-12-17 Mediolanum Farmaceutici Spa Impiego del dermatan solfato nella prevenzione e terapia dell'invecchiamento cerebrale e degli stati di deficit funzionale del sistema nervoso centrale
IL100555A (en) * 1991-02-07 2000-08-31 Hoechst Marion Roussel Inc N-substituted quinoline derivatives their preparation their use for the preparation of medicaments and the pharmaceutical compositions containing them
SK279285B6 (sk) * 1991-05-02 1998-09-09 Daiichi Pharmaceutical Co. Použitie n-(2,6-dimetylfenyl)-2-(2-oxo-1-pyrolidin
RU2106864C1 (ru) * 1995-10-23 1998-03-20 Николай Серафимович Зефиров Средство для лечения болезни альцгеймера

Also Published As

Publication number Publication date
EP1181024A1 (en) 2002-02-27
ES2237425T3 (es) 2005-08-01
AU764743B2 (en) 2003-08-28
ZA200109331B (en) 2002-08-28
KR20020005033A (ko) 2002-01-16
WO2000069444A1 (en) 2000-11-23
PT1181024E (pt) 2005-06-30
PL198016B1 (pl) 2008-05-30
NO20015544D0 (no) 2001-11-13
AU4405200A (en) 2000-12-05
AU764743C (en) 2004-03-18
JP2002544233A (ja) 2002-12-24
KR100711142B1 (ko) 2007-04-24
DK1181024T3 (da) 2005-06-13
US6979680B1 (en) 2005-12-27
HUP0201100A3 (en) 2003-03-28
ATE288761T1 (de) 2005-02-15
HK1039903B (en) 2005-08-26
CZ20014092A3 (cs) 2002-04-17
EP1181024B1 (en) 2005-02-09
CA2373975A1 (en) 2000-11-23
IT1312107B1 (it) 2002-04-04
CN1178667C (zh) 2004-12-08
HK1039903A1 (en) 2002-05-17
IL146458A0 (en) 2002-07-25
DE60018061D1 (de) 2005-03-17
DE60018061T2 (de) 2006-04-13
ITMI991066A1 (it) 2000-11-14
PL352070A1 (en) 2003-07-28
HUP0201100A2 (hu) 2002-07-29
RU2248800C2 (ru) 2005-03-27
CN1350459A (zh) 2002-05-22
NO328902B1 (no) 2010-06-14

Similar Documents

Publication Publication Date Title
NO20015544D0 (no) Glykosaminoglykaner med en gjennomsnittlig molekylvekt lik
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
WO2003053330A3 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer’s disease and conditions associated with glycogen synthase kinase-3
MA25875A1 (fr) Nouveaux derives de l'acide aminodicarboxylique presentant des proprietes pharmaceutiques.
AP1853A (en) Arylmethyl-carbonylamino-thiazole derivatives and their use as antitumor agents.
UA48946C2 (uk) Арилалкілдіазинони, спосіб їх одержання (варіанти), фармацевтичний склад, спосіб його одержання та спосіб лікування
CY1110745T1 (el) Παραγωγα πυρρολιδονης ως αναστολεις μαοβ
CA2171882A1 (en) Inhibitors of .beta.-amyloid protein production
NZ284846A (en) 1-substituted-pyrazolo[3,4-b]pyridin-5-carboxylic acid derivatives, preparation, use, intermediates and pharmaceutical compositions thereof
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
MY133479A (en) Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
DE69912808D1 (de) Verwendung von Hymenialdisin und dessen Derivaten zur Herstellung therapeutischer Mittel
MD1838F2 (en) 5,6-dichlorbenzimidazole derivatives, process for obtaining thereof, pharmaceutical composition and method of treatment or prevention of herpetic viral infections
SE0104341D0 (sv) New use
AU2002314914A1 (en) Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases
WO2000045800A3 (en) Immunosurpressive effects of pteridine derivatives
GEP20033081B (en) Pharmaceutical Agents for Treatment of Parkinson's Disease, ADFD and Microadenomas
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
DE50211929D1 (en) Pyrimidinderivate
AU3083899A (en) (in vitro) formation of congophilic maltese-cross amyloid plaques to identify anti-plaque therapeutics for the treatment of alzheimer's and prion diseases
PL346143A1 (en) Tan-1057 derivatives
CA2217513A1 (en) Pharmaceutical agents for the treatment of alzheimer's disease
UA42731C2 (uk) Арилалкілтіадіазинони, спосіб їх отримання, фармацевтична композиція, спосіб її отримання, спосіб лікування
WO2001083449A3 (en) Rigid pyrrolidone modulators of pkc

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees